article thumbnail

Drug safety update says fluoroquinolone antibiotics should be last resort

Hospital Pharmacy Europe

This is a strengthening of previous regulations from August 2023 , which said that fluoroquinolones should not be prescribed for mild-to-moderate or self-limiting infections, or non-bacterial conditions. The updated drug safety update followed a review into the risk of long-lasting or disabling reactions to fluoroquinolone antibiotics.

article thumbnail

A new dawn of the genomic age: five areas set to be transformed in 2023

pharmaphorum

2023 is set to usher in a new era of genomics, and here are five areas where we should see significant advances. Moreover, research has shown that genetic testing can reduce adverse reactions to drugs by nearly one third. The post A new dawn of the genomic age: five areas set to be transformed in 2023 appeared first on.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Gilead to Presents P-III (TROPiCS-02) Study Results of Trodelvy (sacituzumab govitecan) for Pre-Treated HR+/HER2- Metastatic Breast Cancer at ASCO 2023

PharmaShots

with no new safety signals, the discontinuation rate due to adverse reactions (6% vs 4%) Ref: Gilead | Image: Gilead Related News:- Gilead and Arcus Present P-II Study (ARC-7) Results of Domvanalimab as 1L Treatment of Non-Small Cell Lung Cancer at ASCO 2023 PharmaShots! vs 11.2mos.), PFS rates at 6/12/18mos. vs 29.4%)/ (21.7%

article thumbnail

Innovative biologic for myasthenia gravis granted European approval

European Pharmaceutical Review

New European approval for generalised myasthenia gravis treatment EC approval of rozanolixizumab is supported by data from the Phase III MycarinG study , published in The Lancet Neurology in May 2023, according to UCB. Healthcare professionals are asked to report any suspected adverse reactions.

article thumbnail

First-in-class phosphate absorption inhibitor approved by FDA

European Pharmaceutical Review

However, in the trials, the only observed adverse reaction for the treatment was diarrhoea. XPHOZAH is expected to be available to eligible patients in the US in November 2023. Overall, the data showed that XPHOZAH significantly reduced elevated serum phosphorus in patients receiving maintenance hemodialysis.

FDA 119
article thumbnail

mRNA-1345 effective against RSV-associated lower respiratory tract infections in older adults

Hospital Pharmacy Europe

Commonly reported adverse effects were generally mild to moderate in severity e.g., injection site pain, fatigue, headache, myalgia and arthralgia. In fact, only 4% of systemic adverse reactions reported for the vaccine were grade 3 or higher (i.e., of localised adverse reactions, at grade 3 or above.

article thumbnail

mRNA vaccine trial shows efficiency in older adults with RSV

European Pharmaceutical Review

To date, most solicited adverse reactions were mild or moderate. The most commonly reported solicited adverse reactions in the mRNA-1345 group were injection site pain, fatigue, headache, myalgia, and arthralgia. Based on the study results, Moderna intends to submit for regulatory approval in the first half of 2023.

Vaccines 105